

Association of polymorphisms in *FADS* gene with age-related changes in serum phospholipid polyunsaturated fatty acids and oxidative stress markers in middle-aged nonobese men

Seul Hee Hong^{1,*}
Jung Hyun Kwak^{2,*}
Jean Kyung Paik³
Jey Sook Chae²
Jong Ho Lee^{1,2}

¹National Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, ²Research Institute of Science for Aging, Yonsei University, Seoul, South Korea; ³Department of Food and Nutrition, Eulji University, Gyeonggi-do, South Korea.

*These authors contributed equally to this work

Background: To investigate the association of *FADS* gene polymorphisms with age-related changes in polyunsaturated fatty acids (PUFAs) in serum phospholipids and oxidative stress markers.

Methods: We genotyped 122 nonobese men aged 35–59 years without any known diseases at baseline for rs174537 near *FADS1* (*FEN1* rs174537G > T), *FADS2* (rs174575, rs2727270), and *FADS3* (rs1000778), and followed them for 3 years.

Results: Among the four single-nucleotide polymorphisms, the minor variants of rs174537 and rs2727270 were significantly associated with lower concentrations of long-chain PUFAs. However, rs174537G > T showed stronger association. At baseline, men with the rs174537T allele had lower arachidonic acid (AA) and AA/linoleic acid (LA), and higher interleukin (IL)-6 levels than rs174537GG counterparts. After 3 years, rs174537GG men had significantly increased AA ($P = 0.022$), AA/dihomo- γ -linolenic acid (DGLA) ($P = 0.007$), docosapentaenoic acid (DPA), low-density lipoprotein (LDL) cholesterol, and oxidized LDL (ox-LDL), but decreased eicosatrienoic acid. The rs174537T group showed significantly increased γ -linolenic acid and ox-LDL, and decreased eicosadienoic acid, eicosapentaenoic acid (EPA)/ α -linolenic acid (ALA), and IL-6. After 3 years, the rs174537T group had lower AA ($P < 0.001$), AA/DGLA ($P = 0.019$), EPA, DPA, EPA/ALA, and urinary 8-epi-prostaglandin $F_{2\alpha}$ (8-epi-PGF_{2 α}) ($P = 0.011$) than rs174537GG. Changes in AA ($P = 0.001$), AA/DGLA ($P = 0.017$), EPA, DPA, EPA/ALA, and urinary 8-epi-PGF_{2 α} ($P < 0.001$) were significantly different between the groups after adjusting for baseline values. Overall, changes in AA positively correlated with changes in urinary 8-epi-PGF_{2 α} ($r = 0.249$, $P = 0.007$), plasma ox-LDL ($r = 0.199$, $P = 0.045$), and serum IL-6 ($r = 0.289$, $P = 0.004$).

Conclusion: Our data show that *FADS* polymorphisms can affect age-associated changes in serum phospholipid long-chain PUFAs, Δ 5-desaturase activity, and oxidative stress in middle-aged nonobese men. In particular, the rs174537T allele did not show the age-associated increases in AA and Δ 5-desaturase activity seen with the rs174537GG genotype.

Keywords: *FADS* gene, age-related changes, serum phospholipid polyunsaturated fatty acids, oxidative stress markers, nonobese men

Correspondence: Jong Ho Lee
National Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-749, South Korea
Tel +82 2 2123 3122
Fax +82 2 364 9605
Email jhlee@yonsei.ac.kr

Introduction

The concentrations and ratios of fat types that people eat have shifted, with marked increases in saturated and ω 6 polyunsaturated fatty acids (PUFAs).¹ In South Korea, similar profound quantitative and qualitative changes in fat intake have occurred in the last four decades, particularly the rising intake of saturated fatty acids and ω 6 PUFAs.²

Dietary PUFAs influence the fatty acid (FA) composition of tissue lipids.³ However, interindividual variability in serum phospholipid FA, as markers of the FA status of an individual, can be attributed to a combination of dietary factors and genetic variation. The key enzymes in PUFA metabolism are $\Delta 5$ -desaturase and $\Delta 6$ -desaturase, which are encoded by the *FADS1* and *FADS2* genes, respectively.⁴⁻⁶ These two genes are located in the desaturase gene cluster on chromosome 11q12–13.1. This cluster also includes *FADS3*, a gene that shares 52% and 62% sequence identity with the *FADS1* and *FADS2* genes, respectively, and encodes a desaturase of unknown activity.⁴ In addition, dietary PUFAs have been shown to suppress the activity of stearoyl-coenzyme A (CoA) desaturase ($\Delta 9$ -desaturase),⁷ which is encoded by the stearoyl-CoA desaturase gene family and the rate-limiting enzyme in the cellular synthesis of monounsaturated FA (oleic acid; 18:1 n-9) from saturated FA (stearic acid; 18:0 n-9).⁸

A genome-wide association study for plasma PUFAs showed strong evidence for association with the region of chromosome 11 that encodes *FADS1*, *FADS2*, and *FADS3*.⁹ The most significant association was between the single-nucleotide polymorphism (SNP) rs174537 (flap structure-specific endonuclease [*FEN1*] near *FADS1* and arachidonic acid (AA, 20:4 ω 6). Recently, Mathias et al¹ suggested that variants in the $\Delta 5$ -desaturase enzymatic step likely regulate the efficiency of conversion of medium-chain PUFAs, such as dietary linoleic acid (LA, 18:2 ω 6), to potentially inflammatory PUFAs, such as AA. In our previous study, we investigated the association of *FADS* polymorphism, including rs174537, with PUFAs in serum phospholipids and coronary artery disease-related biomarkers in South Koreans through a case-control study. We also determined the effect of these SNPs on lipid peroxides. We found that rs174537T was associated with a lower proportion of AA in serum phospholipids and reduced coronary artery disease risk, in association with reduced total and low-density lipoprotein cholesterol (LDL-C) and lipid peroxides.¹⁰ However, there are no reports on the effect of *FADS* polymorphisms on age-associated changes in serum phospholipid PUFA composition, proinflammatory cytokines, or oxidative stress markers. Therefore, we followed 122 nonobese men aged between 35 and 59 years without a history of known diseases at baseline for 3 years to investigate the association of *FADS* polymorphisms, including rs174537, with age-associated changes in serum phospholipid PUFA composition. We also examined the effects of these SNPs on lipid peroxides and oxidative stress markers, including oxidized-LDL (ox-LDL) and urinary 8-epi-prostaglandin $F_{2\alpha}$ (8-epi-PGF_{2 α}).

Materials and methods

Study population

A total of 160 healthy nonobese ($18.5 \leq$ body mass index [BMI] < 30 kg/m²) men aged 35–59 years were recruited at a health-promotion center at the National Health Insurance Corporation Ilsan Hospital in South Korea between August and December 2006. Subjects were sedentary, had no history of known disease, and completed a personal health and medical history questionnaire, which served as a screening tool. Exclusion criteria were type 2 diabetes, cardiovascular disease, psychiatric problems, and use of any medication. Written informed consent was obtained from all participants, and the study protocol was approved by the Institutional Review Board of Yonsei University.

Anthropometric parameters and blood collection

Body weight and height were measured in the morning while participants were unclothed and not wearing shoes. BMI was calculated as body weight in kilograms divided by the square of the height in meters (kg/m²). Systolic and diastolic blood pressures (SBP and DBP, respectively) were obtained from the left arm of seated patients with an automatic blood pressure monitor (TM-2654; A&D, Tokyo, Japan) after 20 minutes of rest. After overnight fasting, venous blood samples were collected in ethylenediaminetetraacetic acid-treated or plain tubes, separated into plasma and serum, and then stored at -70°C until analysis.

Genotyping of *FADS* gene polymorphisms

Genomic DNA was extracted from 5 mL whole blood using a commercially available DNA isolation kit (Wizard genomic DNA purification kit; Promega, Fitchburg, WI, USA) according to the manufacturer's protocol. Based on previous reports of genetic studies and public databases on the *FADS* gene cluster^{9,11} and the HapMap project (<http://www.hapmap.org>), eight relevant *FADS* SNPs were prescreened and four SNPs (*FEN1* rs174537G $>$ T, *FADS2* rs174575C $>$ G, *FADS2* rs2727270C $>$ T, *FADS3* 1000778C $>$ T) were selected for further analysis (Table S1).

Serum lipid profile and fasting glucose

Fasting serum total cholesterol and triglyceride (TG) were measured using a 7150 Autoanalyzer (Hitachi, Tokyo, Japan). After precipitation of serum chylomicrons using dextran sulfate magnesium, HDL-cholesterol concentrations in the supernatants were enzymatically measured. LDL-C was estimated indirectly using the Friedewald formula for subjects

with serum TG concentrations <400 mg/dL (4.52 mol/L). In subjects with serum TG concentrations \geq 4.52 mol/L (400 mg/mL), LDL-C was directly measured by an enzymatic method on the 7150 Autoanalyzer. Fasting glucose was measured by the glucose oxidase method using a glucose analyzer (Beckman Coulter, Brea, CA, USA).

Plasma ox-LDL and serum high-sensitivity C-reactive protein

Plasma ox-LDL was measured using an enzyme immunoassay (Merckodia, Uppsala, Sweden). The resulting color reaction was read at 450 nm on a Wallac Victor² multilabel counter (PerkinElmer, Waltham, MA, USA). High-sensitivity C-reactive protein (hs-CRP) levels were measured on an Express PlusTM autoanalyzer (Chiron Diagnostics Co., Walpole, MA, USA) using commercially available hs-CRP-Latex (II) X2 kits (Seiken Laboratories Ltd., Tokyo, Japan) that allowed detection of CRP in the range of 0.001–31 mg/dL.

Urinary 8-epi-PGF_{2 α} and serum cytokine levels

Urine was collected in polyethylene tubes containing 1% butylated hydroxytoluene after a 12-hour fast. The tubes were immediately covered with aluminum foil and stored at -70°C until analysis. 8-epi-PGF_{2 α} was measured using an enzyme immunoassay (Bioxytech Urinary 8-epi-PGF_{2 α} Assay Kit, Oxis International, Portland, OR, USA), and the resulting color reaction was read at 650 nm using a Wallac Victor² multilabel counter. Urinary creatinine was determined by the alkaline picrate (Jaffe) reaction. Urinary 8-epi-PGF_{2 α} concentrations were expressed as pg/mg creatinine. Levels of interleukin (IL)-6 and tumor necrosis factor (TNF)- α in serum were measured using the Bio-Plex Reagent Kit on a Bio-Plex instrument (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions.

FA composition in serum phospholipids

Serum phospholipid FA composition was analyzed by gas chromatography (7890A; Hewlett Packard, Palo Alto, CA, USA) using a modification of a previously described method.^{12,13} Individual FAs were calculated as a relative percentage of the total of 26 FAs (set as 100%) using GC ChemStation software revision B.04.02 (Agilent Technologies, Santa Clara, CA, USA). The activities of Δ 5 desaturase and Δ 6 desaturase were estimated as the ratios of AA to DGLA and γ -linolenic acid (GLA; 18:3 ω 6) to LA, respectively.

Assessment of dietary intake and physical activity level

The duration of the study was 3 years. At baseline, usual dietary intake for each subject was assessed using a semi-quantitative food-frequency questionnaire and 24-hour recall method.¹⁴ Subjects were encouraged to maintain their body weight within \pm 2 kg and given general oral and written information about healthy food choices and exercise at baseline and at a subsequent visit (after 3 years). Subjects were instructed by trained dietitians and were also asked to keep food records for 3 days (2 weekdays and 1 weekend day) at each visit. Nutrient intake was determined and calculated as mean values from the 3-day food record using Can-Pro (Korean Nutrition Society, Seoul, South Korea), based on food-composition tables from the National Rural Living Science Institute in South Korea. Total energy expenditure (kcal/d) was calculated from activity patterns, including basal metabolic rate calculated with the Harris–Benedict equation, physical activity for 24 hours, and specific dynamic action of food.

Statistical analysis

Statistical analyses were performed using SPSS version 12.0 for Windows (IBM, Armonk, NY, USA). Hardy–Weinberg equilibrium and linkage disequilibrium tests were examined using Haploview 4.1 (Broad Institute, Cambridge, MA, USA). Frequencies were compared by the Chi-square test. We examined whether each variable was normally distributed before statistical testing, and logarithmic transformation was performed for skewed variables. Paired *t*-tests were used to test between baseline and follow-up values. Differences in clinical variables between the rs174537GG and T-allele carrier groups were tested by independent *t*-test, and a general linear model test was applied to adjust for baseline values. Pearson's correlation coefficients were used to examine the relationships between variables. For descriptive purposes, mean values are presented using untransformed and unadjusted values. Results are expressed as means \pm standard error or percentage. A two-tailed value of $P < 0.05$ was considered statistically significant.

Results

Clinical characteristics, serum phospholipid FA composition, and macronutrient intake at baseline and 3-year follow-up

Among the enrolled men ($n = 160$), 38 dropped out for personal reasons or poor compliance, leaving 122 men at 3 years. Clinical characteristics, serum phospholipid FA composition, and macronutrient intake at baseline and 3-year follow-up

are shown in Table 1. After 3 years, subjects showed an increase in LDL-C ($P = 0.018$), ox-LDL ($P < 0.001$), serum phospholipid GLA ($P = 0.024$), and AA ($P = 0.043$). HDL-C ($P = 0.001$), IL-6 ($P = 0.004$), and serum phospholipid eicosadienoic acid (20:2 ω 6) ($P = 0.016$) decreased. There was no significant difference in total energy intake or macronutrient intake between baseline and 3-year follow-up (Table 1).

Table 1 Clinical characteristics, PUFA composition in serum phospholipids, and macronutrient intake at baseline and at 3 years

n = 122	Baseline	3-year follow-up	P
Age (years)	46.7 \pm 0.58	49.7 \pm 0.60	<0.001
Body mass index (kg/m ²)	24.0 \pm 0.20	24.1 \pm 0.20	0.501
Systolic blood pressure (mmHg)	120.3 \pm 1.10	119.6 \pm 1.29	0.483
Diastolic blood pressure (mmHg)	74.5 \pm 0.88	74.8 \pm 1.05	0.679
Fasting glucose (mg/dL) [§]	92.1 \pm 0.86	93.5 \pm 0.85	0.121
Triglyceride (mg/dL) [§]	131.3 \pm 6.96	133.4 \pm 7.61	0.901
Total cholesterol (mg/dL) [§]	191.3 \pm 3.10	193.3 \pm 3.07	0.367
LDL cholesterol (mg/dL) [§]	117.0 \pm 3.17	121.7 \pm 2.85	0.018
HDL cholesterol (mg/dL) [§]	49.6 \pm 1.15	46.4 \pm 1.08	0.001
hs-CRP (mg/dL) [§]	1.64 \pm 0.42	1.55 \pm 0.29	0.601
Serum TNF- α (pg/mL) [§]	11.4 \pm 1.01	10.4 \pm 0.88	0.856
Serum IL-6 (pg/mL) [§]	4.58 \pm 0.33	3.63 \pm 0.26	0.004
Oxidized LDL (U/L) [§]	34.8 \pm 1.26	44.7 \pm 1.15	<0.001
8-epi-PGF _{2α} (pg/mg creatinine) [§]	1318.6 \pm 46.6	1363.7 \pm 45.2	0.323
PUFA composition (%) in serum PL			
Total polyunsaturated ω 6 FA	19.1 \pm 0.38	19.1 \pm 0.46	0.983
18:2 (ω 6)	12.0 \pm 0.28	11.8 \pm 0.32	0.621
18:3 (ω 6)	0.17 \pm 0.01	0.20 \pm 0.01	0.024
20:2 (ω 6)	0.67 \pm 0.12	0.43 \pm 0.08	0.016
20:3 (ω 6)	1.44 \pm 0.04	1.43 \pm 0.05	0.977
20:4 (ω 6)	4.36 \pm 0.14	4.78 \pm 0.19	0.043
Total polyunsaturated ω 3 FA	4.66 \pm 0.17	5.03 \pm 0.20	0.123
18:3 (ω 3)	0.17 \pm 0.02	0.19 \pm 0.01	0.425
20:3 (ω 3)	0.09 \pm 0.01	0.07 \pm 0.00	0.054
20:5 (ω 3)	1.12 \pm 0.05	1.26 \pm 0.07	0.115
22:5 (ω 3)	0.57 \pm 0.03	0.58 \pm 0.03	0.727
22:6 (ω 3)	2.71 \pm 0.12	2.93 \pm 0.13	0.171
Estimates of daily nutrient intakes			
Total energy intake (kcal)	2440.2 \pm 19.1	2425.7 \pm 15.8	0.399
Carbohydrate (% of energy)	61.5 \pm 0.13	61.5 \pm 0.08	0.672
Protein (% of energy)	16.8 \pm 0.12	16.5 \pm 0.07	0.114
Fat (% of energy)	21.6 \pm 0.14	21.7 \pm 0.11	0.794
Total energy expenditure (kcal)	2361.5 \pm 16.7	2333.0 \pm 13.7	0.085

Notes: [§]Tested by logarithmic transformation, P-values derived from paired t-test. Values are means \pm standard error.

Abbreviations: PUFA, polyunsaturated fatty acid; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; TNF, tumor necrosis factor; IL, interleukin; 8-epi-PGF_{2 α} , urinary 8-epi-prostaglandin F_{2 α} .

Genotype distribution of four selected SNPs

Genotype distributions in Hardy–Weinberg equilibrium with 41.0% GG, 47.5% GT, and 11.5% TT at position rs174537; 88.5% CC, 9.8% CG, and 1.6% GG at position rs174575; 48.4% CC, 44.3% CT, and 7.4% TT at position rs2727270; and 49.2% CC, 38.5% CT, and 12.3% TT at position rs1000778. The major alleles were G at position rs174537 (frequency 0.648, $P = 0.647$), C at rs174575 (frequency 0.934, $P = 0.087$), C at rs2727270 (frequency 0.705, $P = 0.480$), and C at position rs1000778 (frequency 0.684, $P = 0.233$). Because the *FADS3* rs1000778C > T genotype-related PUFA was not significantly different among serum phospholipids, and the *FADS2* rs174575 genotype only showed a trend toward an association with serum phospholipid PUFA (data not shown), we did not perform further analysis on *FADS3* rs1000778C > T and *FADS2* rs174575C > G. The genotype and haplotype distributions of *FEN1* rs174537 and *FADS2* rs2727270 were both associated with PUFAs in serum phospholipids. However, because haplotype analysis did not provide information beyond that revealed by each SNP (data not shown), we present only the results of *FEN1* rs174537 and *FADS2* rs2727270.

Serum phospholipid FA composition according to genotypes

At baseline, men with the *FEN1* rs174537T allele showed a lower proportion of AA ($P = 0.007$) and lower ratio of AA to LA ($P = 0.007$) in serum phospholipids than those with rs174537GG (Table 2). After 3 years, men with rs174537GG showed a significant increase in AA ($P = 0.022$), ratio of AA to DGLA ($P = 0.007$, Figure 1), and docosapentaenoic acid (DPA; 22:5 ω 3) ($P = 0.044$), but a significant decrease in eicosatrienoic acid (20:3 ω 3) ($P = 0.037$, Table 2). Carriers of the rs174537T allele showed a significant increase in GLA ($P = 0.031$) and a significant decrease in EDA ($P = 0.030$), and the ratio of eicosapentaenoic acid (EPA; 20:5 ω 3) to α -linolenic acid (ALA; 18:3 ω 3) ($P = 0.024$). At 3-year follow-up, men with the rs174537T allele showed lower AA ($P < 0.001$), AA/DGLA ($P = 0.019$, Figure 1), EPA ($P = 0.010$), DPA ($P = 0.016$), and EPA/ALA ($P = 0.048$) than rs174537GG carriers. Changes in AA ($P = 0.001$), AA/DGLA ($P = 0.017$, Figure 1), EPA ($P = 0.004$), DPA ($P = 0.011$), and EPA/ALA ($P = 0.048$) were significantly different between rs174537GG men and rs174537T allele carriers after adjusting for baseline values (Table 2). Similar but weaker associations of *FADS2* rs2727270 with PUFAs were also found (Table S2).

Table 2 Associations of *FEN1* rs174537 genotypes with PUFA composition in serum phospholipids in men at baseline and 3-year follow-up

	<i>FEN1</i> rs174537					
	GG (n = 50)	P ^a	T allele (n = 72)	P ^a	P ^b	P ^c
PUFA composition (%) in serum PL						
18:2 (ω6)						
Baseline	11.9 ± 0.42	0.957	12.1 ± 0.38	0.518	0.685	
Follow-up	11.9 ± 0.52		11.8 ± 0.41		0.835	
Change	0.03 ± 0.52		-0.34 ± 0.53		0.627	0.753
18:3 (ω6)						
Baseline	0.18 ± 0.02	0.303	0.16 ± 0.01	0.031	0.413	
Follow-up	0.20 ± 0.01		0.20 ± 0.01		0.584	
Change	0.02 ± 0.02		0.03 ± 0.01		0.659	0.652
20:2 (ω6)						
Baseline	0.61 ± 0.19	0.158	0.72 ± 0.16	0.030	0.665	
Follow-up	0.33 ± 0.03		0.51 ± 0.14		0.287	
Change	-0.28 ± 0.19		-0.21 ± 0.09		0.733	0.313
20:3 (ω6)						
Baseline	1.53 ± 0.07	0.926	1.37 ± 0.06	0.903	0.081	
Follow-up	1.53 ± 0.09		1.36 ± 0.06		0.101	
Change	0.01 ± 0.10		-0.01 ± 0.08		0.880	0.184
20:4 (ω6)						
Baseline	4.79 ± 0.23	0.022	4.04 ± 0.16	0.587	0.007	
Follow-up	5.61 ± 0.30		4.17 ± 0.21		<0.001	
Change	0.81 ± 0.34		0.14 ± 0.25		0.108	0.001
18:3 (ω3)						
Baseline	0.17 ± 0.03	0.742	0.17 ± 0.03	0.463	0.998	
Follow-up	0.19 ± 0.01		0.20 ± 0.02		0.589	
Change	0.01 ± 0.03		0.02 ± 0.03		0.760	0.591
20:3 (ω3)						
Baseline	0.10 ± 0.02	0.037	0.08 ± 0.01	0.613	0.153	
Follow-up	0.07 ± 0.00		0.07 ± 0.00		0.392	
Change	-0.04 ± 0.02		-0.01 ± 0.01		0.108	0.408
20:5 (ω3)						
Baseline	1.19 ± 0.08	0.090	1.07 ± 0.06	0.787	0.231	
Follow-up	1.49 ± 0.14		1.09 ± 0.07		0.010	
Change	0.30 ± 0.18		0.02 ± 0.08		0.153	0.004
22:5 (ω3)						
Baseline	0.54 ± 0.04	0.044	0.59 ± 0.05	0.213	0.441	
Follow-up	0.66 ± 0.04		0.53 ± 0.03		0.016	
Change	0.12 ± 0.06		-0.06 ± 0.05		0.019	0.011
22:6 (ω3)						
Baseline	2.81 ± 0.20	0.134	2.64 ± 0.15	0.649	0.495	
Follow-up	3.20 ± 0.20		2.73 ± 0.16		0.071	
Change	0.39 ± 0.26		0.09 ± 0.20		0.354	0.088
20:4 (ω6)/20:3 (ω6)						
Baseline	3.26 ± 0.15	0.007	3.33 ± 0.35	0.808	0.882	
Follow-up	3.96 ± 0.25		3.24 ± 0.19		0.019	
Change	0.70 ± 0.25		-0.09 ± 0.36		0.101	0.017
20:4 (ω6)/18:2 (ω6)						
Baseline	0.43 ± 0.03	0.202	0.34 ± 0.01	0.237	0.007	
Follow-up	0.53 ± 0.06		0.41 ± 0.05		0.146	
Change	0.10 ± 0.07		0.06 ± 0.05		0.719	0.185
20:5 (ω3)/18:3 (ω3)						
Baseline	9.55 ± 0.88	0.328	9.06 ± 0.87	0.024	0.694	
Follow-up	8.42 ± 0.71		6.69 ± 0.53		0.048	
Change	-1.13 ± 1.14		-2.37 ± 1.02		0.426	0.048

Notes: ^aValues derived from paired t-test; ^bvalues derived from independent t-test; ^cvalues derived after adjusting for baseline values. Values are means ± standard error.

Abbreviations: PUFA, polyunsaturated fatty acid; PL, phospholipid.




Figure 1 Serum phospholipid AA (20:4 ω6), the ratio of 20:4 ω6/20:3 ω6, and urinary levels of 8-epi-PGF_{2α} according to FEN1 rs174537 G > T in men at baseline (□) and 3-year follow-up (■).

Notes: † $P < 0.05$; †† $P < 0.01$ for baseline vs 3 years, tested by paired *t*-test; ‡ $P < 0.05$; †‡ $P < 0.01$; †‡‡ $P < 0.001$ for GG vs T-allele group, tested by independent *t*-test; *after adjusting for baseline values. Changes are differences between baseline and 3 years; values are means ± standard error.

Abbreviation: 8-epi-PGF_{2α}, urinary 8-epi-prostaglandin F_{2α}.

LDL-cholesterol, hs-CRP, cytokines, and oxidative stress markers according to genotypes

At baseline, men with the FEN1 rs174537T allele showed higher serum IL-6 than those with rs174537GG ($P = 0.038$, Table 3). After 3 years, men with rs174537GG showed a significant increase in serum LDL-C ($P = 0.043$) and plasma ox-LDL ($P < 0.001$). Carriers of the rs174537T allele showed a significant decrease in IL-6 ($P = 0.001$) and a significant increase in ox-LDL ($P < 0.001$). At 3-year follow-up, men with the rs174537T allele showed lower urinary PGF_{2α} levels ($P = 0.011$) than rs174537GG carriers. Changes in urinary PGF_{2α} levels ($P < 0.001$) were significantly different between rs174537GG and rs174537T allele carriers after adjusting for baseline values (Figure 1). Additionally, changes in serum TNF-α ($P = 0.089$) tended to be different (Table 3). Similar associations were found between FADS2 rs2727270 and LDL-C, hs-CRP, cytokines, and oxidative stress markers (Table S3).

Relation of serum phospholipid AA with oxidative stress markers and cytokines

Pearson correlation analysis showed that the changes in the AA proportion in serum phospholipids were positively correlated with changes in urinary 8-epi-PGF_{2α} levels ($r = 0.249$, $P = 0.007$), plasma ox-LDL ($r = 0.199$, $P = 0.045$), and serum IL-6 ($r = 0.289$, $P = 0.004$) in all subjects (Figure 2).

There was a marginal correlation between changes in serum phospholipid AA and changes in serum TNF-α ($r = 0.191$, $P = 0.058$). Additionally, changes in urinary 8-epi-PGF_{2α} levels were positively correlated with changes in serum IL-6 ($r = 0.242$, $P = 0.015$) and TNF-α ($r = 0.246$, $P = 0.013$). Changes in serum IL-6 were positively correlated with changes in serum TNF-α ($r = 0.464$, $P < 0.001$) and hs-CRP ($r = 0.507$, $P < 0.001$, Table 4).

Discussion

The major finding of this study is that FADS polymorphisms may affect age-associated changes in serum phospholipid long-chain PUFAs, Δ5-desaturase activity, and oxidative stress in middle-aged nonobese men. At 3-year follow-up, there were significant differences between men with FEN1 rs174537GG and those with the 174537T allele in changes in AA, and Δ5-desaturase activity (determined by the ratio of AA/DGLA), as well as urinary levels of PGF_{2α}, one of the radical peroxides of AA, and an indicator of oxidative stress.¹⁵ In particular, the rs174537T allele did not show the age-associated increases in AA and Δ5-desaturase activity seen with the rs174537GG genotype. Therefore, our data show that FADS polymorphisms could affect age-associated changes in serum phospholipid long-chain PUFAs, Δ5-desaturase activity, and oxidative stress in middle-aged nonobese men.

Similar to previous studies,^{1,16} the minor variants of rs174537G > T and rs2727270 were significantly associated with lower concentrations of long-chain PUFAs.

Table 3 Associations of *FEN1* rs174537 genotypes with LDL-cholesterol, hs-CRP, cytokines, and oxidative stress markers in men at baseline and 3-year follow-up

	<i>FEN1</i> rs174537					
	GG (n = 50)	P ^a	T allele (n = 72)	P ^a	P ^b	P ^c
LDL cholesterol (mg/dL)						
Baseline [§]	117.8 ± 4.61	0.043	116.5 ± 4.31	0.145	0.830	
Follow-up [§]	123.3 ± 3.92		120.7 ± 3.99		0.498	
Change	5.50 ± 3.11		4.21 ± 3.25		0.785	0.677
hs-CRP (mg/dL)						
Baseline [§]	1.38 ± 0.35	0.828	1.82 ± 0.67	0.424	0.751	
Follow-up [§]	1.46 ± 0.35		1.62 ± 0.43		0.603	
Change	0.08 ± 0.18		-0.20 ± 0.79		0.769	0.623
Serum IL-6 (pg/mL)						
Baseline [§]	3.83 ± 0.42	0.557	5.07 ± 0.47	0.001	0.038	
Follow-up [§]	3.90 ± 0.46		3.44 ± 0.30		0.702	
Change	0.07 ± 0.49		-1.63 ± 0.54		0.030	0.307
Serum TNF- α (pg/mL)						
Baseline [§]	11.7 ± 1.42	0.943	11.2 ± 1.40	0.863	0.467	
Follow-up [§]	12.0 ± 2.02		9.26 ± 0.55		0.376	
Change	0.33 ± 2.27		-1.95 ± 1.40		0.369	0.089
8-epi-PGF _{2α} (pg/mg creatinine)						
Baseline [§]	1342.7 ± 60.4	0.156	1301.0 ± 67.9	0.995	0.349	
Follow-up [§]	1531.8 ± 86.7		1240.1 ± 40.1		0.011	
Change	189.2 ± 104.5		-60.9 ± 78.2		0.053	<0.001
Oxidized LDL (U/L)						
Baseline [§]	33.1 ± 1.77	<0.001	36.1 ± 1.76	<0.001	0.292	
Follow-up [§]	45.2 ± 1.53		44.3 ± 1.64		0.373	
Change	12.2 ± 1.83		8.19 ± 1.70		0.119	0.241

Notes: [§]Tested by logarithmic transformation; ^avalues derived from paired *t*-test; ^bvalues derived from independent *t*-test; ^cvalues derived after adjusting for baseline value. Values are means ± standard error.

Abbreviations: PUFA, polyunsaturated fatty acid; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; TNF, tumor necrosis factor; IL, interleukin; 8-epi-PGF_{2 α} , urinary 8-epi-prostaglandin F_{2 α} .

However, rs174537G > T showed stronger association with changes in AA, Δ 5-desaturase activity, EPA, DPA, and EPA/ALA than rs2727270. Although numerous SNPs in the *FADS* gene cluster were reported to be significantly associated with FA alterations in tissues, such as serum and red blood cell membranes,^{1,9,11,17,18} a recent genome-wide association study⁹ found the most significant association to that of rs174537 with AA. However, rs174537 is located in an intron and in linkage disequilibrium with rs174546 ($r^2 = 0.99$) and rs3834458 ($r^2 = 0.98$), which are candidates for a direct influence on gene expression.^{11,19} Therefore, it is possible that this variant is a marker of other functional polymorphisms or is in linkage with currently unidentified causal variants affecting FA concentrations.

AA, a precursor of eicosanoids including prostaglandins and leukotrienes, is liberated from the hydrolysis of the *sn*-2 position of glycerophospholipids (phosphatidylcholine).²⁰ Radical peroxidation of AA produces a family of prostaglandin F₂-isomers called F₂-isoprostanes.²¹ One such F₂-isoprostane, 8-epi-PGF_{2 α} , is a sensitive and independent risk marker for

coronary artery disease.^{15,22,23} It is probably released into biological fluids through a phospholipase-mediated pathway and consequently excreted in urine. In this study, the changes in the AA proportion in serum phospholipids were positively correlated with changes in urinary 8-epi-PGF_{2 α} levels as well as changes in serum IL-6. Interestingly, changes in urinary 8-epi-PGF_{2 α} also correlate with changes in IL-6 and TNF- α . This result is consistent with previous findings of a positive association between urinary 8-epi-PGF_{2 α} and circulating proinflammatory cytokines.²⁴

High concentrations of AA may influence the levels of proinflammatory eicosanoids, which in turn appear to be associated with elevated markers of low-level systemic inflammation.²⁵⁻²⁷ Thus, low synthesis and availability of AA have been suggested to mitigate the inflammatory response by altering, for example, eicosanoid levels.²⁸ At 3-year follow-up, men with the rs174537T allele showed lower AA, Δ 5-desaturase activity, and urinary PGF_{2 α} levels compared to those with rs174537GG. In addition, men with the rs174537T allele also showed significant reduction in IL-6 at 3-year follow-up compared to baseline,




Figure 2 Relation of changes in serum phospholipid arachidonic acid with changes in oxidized LDL, urinary 8-epi-PGF_{2α} and serum IL-6 in all male subjects.

Note: Changes are differences between baseline and 3 years.

Abbreviations: 8-epi-PGF_{2α}, urinary 8-epi-prostaglandin F_{2α}; LDL, low-density lipoprotein; IL, interleukin.

and changes in serum TNF- α tended to be different between rs174537GG and rs174537T allele carriers.

Tekola Ayele et al conducted a genome-wide association study of IL-10, IL-1Ra, and IL-6 level in nondiabetic Africans. They reported that IL-6 levels showed genome-wide significant association with one SNP (RP11-314E23.1; chr6:133397598; $P = 8.63 \times 10^{-9}$), but did not confirm an association of IL-6 with *FADS* genotypes.²⁹ In addition, Naitza et al investigated a genome-wide association scan on the levels of markers of inflammation including IL-6; however, they did not find an association of IL-6 with *FADS* genotypes either.³⁰ In our result, at baseline, men with the *FEN1* rs174537T allele showed higher serum IL-6 than those with rs174537GG ($P = 0.038$, Table 3). After adjusting for baseline, changes in IL-6 levels were not significantly different between rs174537GG and rs174537T allele carriers. Thus, we may need to consider further study with an increased number of study subjects in the future to confirm and clarify the result pattern.

Age is known to play an important role in increased LDL oxidation.³¹ After 3 years, LDL-C increased in men with

rs174537GG, and ox-LDL, one of the products of oxidative stress, increased regardless of genotype. Although the change in ox-LDL in subjects with the rs174537T allele was 33% lower than that of men with GG, it failed to reach statistical significance. However, the present findings of direct correlation between serum phospholipid AA and both plasma ox-LDL and urinary 8-epi-PGF_{2α} could suggest a possible role of AA in lipid peroxidation or oxidative stress during aging. More than 95% of the serum phospholipids are phosphatidylcholine, one of the major phospholipids in membranes. Thus, serum phospholipids mirror membrane composition in the body, as markers of the FA status of an individual.³²

Several limitations of this study should be mentioned. First, the small sample size was not conducive to identification of weak associations due to low statistical power. Second, PUFA levels were expressed as a percentage of total FAs in serum phospholipids, not as an absolute concentration. Therefore, we were able to detect relative differences in PUFA levels and $\Delta 5$ -desaturase activity, but unable to decipher the mechanisms, which depend on the absolute values. Third, dietary intake of PUFAs was not investigated in this study, but we confirmed dietary intake of total fat percentage, which did not change for the follow-up period. Finally, we specifically focused on a representative group of South Korean nonobese ($18.5 \leq \text{BMI} < 30 \text{ kg/m}^2$) men aged 35–59 years. Our subjects were not taking any medications or vitamin/mineral supplementations. Therefore, our data cannot be generalized to other ethnic groups or other populations.

Table 4 Correlations between 8-epi-PGF_{2α} and cytokine

	8-epi-PGF _{2α}		IL-6	
	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>
IL-6	0.242	0.015	–	–
TNF- α	0.246	0.013	0.464	<0.001
hs-CRP	0.085	0.364	0.507	<0.001

Abbreviations: 8-epi-PGF_{2α}, urinary 8-epi-prostaglandin F_{2α}; IL, interleukin; TNF, tumor necrosis factor; hsCRP, high-sensitivity C-reactive protein C-reactive protein.

Conclusion

Our data show that *FADS* polymorphisms could affect age-associated changes in serum phospholipid long-chain PUFAs, $\Delta 5$ -desaturase activity, and oxidative stress in middle-aged nonobese men. In particular, the rs174537T allele did not show age-associated increase in AA and $\Delta 5$ -desaturase activity seen in the rs174537GG genotype. Because it has been suggested that appropriate dietary intake of FAs can obviously overcome genetic risk factors,³³ these results provide good evidence for tailoring dietary intervention programs to individuals based on their genetic patterns.

Acknowledgments

This work was supported by the National Research Foundation, Ministry of Education, Science and Technology (Mid-career Researcher Program: 2012-0005604, M10642120002-06 N4212-00210, C00048, and 2012M3A9C4048762), South Korea.

Disclosure

None of the authors had any personal or financial conflicts of interest.

References

- Mathias RA, Vergara C, Gao L, et al. FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. *J Lipid Res.* 2010;51:2766–2774.
- Ailhaud G, Guesnet P, Cunnane SC. An emerging risk factor for obesity: does disequilibrium of polyunsaturated fatty acid metabolism contribute to excessive adipose tissue development? *Br J Nutr.* 2008;100:461–470.
- Karlsson M, Mårild S, Brandberg J, Lönn L, Friberg P, Strandvik B. Serum phospholipid fatty acids, adipose tissue, and metabolic markers in obese adolescents. *Obesity.* 2006;14:1931–1939.
- Marquardt A, Stöhr H, White K, Weber BH. cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. *Genomics.* 2000;66:175–183.
- Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. *J Biol Chem.* 1999;274:471–477.
- Cho HP, Nakamura M, Clarke SD. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. *J Biol Chem.* 1999;274:37335–37339.
- Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). *Prog Lipid Res.* 1995;34:139–150.
- Ntambi JM. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. *J Lipid Res.* 1999;40:1549–1558.
- Tanaka T, Shen J, Abecasis GR, et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS Genet.* 2009;5:e1000338.
- Kwak JH, Paik JK, Kim OY, et al. FADS gene polymorphisms in Koreans: association with $\omega 6$ polyunsaturated fatty acids in serum phospholipids, lipid peroxides, and coronary artery disease. *Atherosclerosis.* 2011;214:94–100.
- Schaeffer L, Gohlke H, Müller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum Mol Genet.* 2006;15:1745–1756.
- Folch J, Lees M, Sloane, Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem.* 1957;226:497–509.
- Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. *J Lipid Res.* 1986;27:114–120.
- Shim JS, Oh KW, Suh I, et al. A study on validity of a 299 semiquantitative food frequency questionnaire of Korean adults. *Korean J Community Nutr.* 2002;7:484–494.
- Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. *Circulation.* 2004;109:843–848.
- Merino DM, Johnston H, Clarke S, et al. Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults. *Mol Genet Metab.* 2011;103:171–178.
- Malerba G, Schaeffer L, Xumerle L, et al. SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. *Lipids.* 2008;43:289–299.
- Bokor S, Dumont J, Spinneker A, et al. Single nucleotide polymorphisms in the FADS gene cluster are associated with delta-5 and delta-6 desaturase activities estimated by serum fatty acid ratios. *J Lipid Res.* 2010;51:2325–2333.
- Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. *Nat Genet.* 2007;39:1202–1207.
- Stafforini DM, Sheller JR, Blackwell TS, et al. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. *J Biol Chem.* 2006;281:4616–4623.
- Voss P, Siems W. Clinical oxidation parameters of aging. *Free Radic Res.* 2006;40:1339–1349.
- Wolfram R, Oguogho A, Palumbo B, Sinzinger H. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). *Eur J Heart Fail.* 2005;7:167–172.
- Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. *Am J Clin Nutr.* 2008;88:630–637.
- Kim OY, Chae JS, Paik JK, et al. Effects of aging and menopause on serum interleukin-6 levels and peripheral blood mononuclear cell cytokine production in healthy nonobese women. *Age (Dordr).* 2012;34:415–425.
- Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. *Circulation.* 2003;108:2317–2322.
- Chilton FH, Rudel LL, Parks JS, Arm JP, Seeds MC. Mechanisms by which botanical lipids affect inflammatory disorders. *Am J Clin Nutr.* 2008;87:498S–503S.
- Pouidel-Tandukar K, Nanri A, Matsushita Y, et al. Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum C-reactive protein levels among Japanese men. *Nutr Res.* 2009;29:363–370.
- Vessby B, Uusitupa M, Hermansen K, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. *Diabetologia.* 2001;44:312–319.
- Tekola Ayele F, Doumatey A, Huang H, et al. Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans. *Immunogenetics.* 2012;64:351–359.
- Naitza S, Porcu E, Steri M, et al. A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. *PLoS Genet.* 2012;8:e1002480.
- Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. *Circulation.* 1998;98:1487–1494.
- Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. *Biochim Biophys Acta.* 1984;779:89–137.
- Lattka E, Illig T, Heinrich J, Koletzko B. Do FADS genotypes enhance our knowledge about fatty acid related phenotypes? *Clin Nutr.* 2010;29:277–287.

Supplementary tables

Table S1 Information for the prescreening of eight single-nucleotide polymorphisms (SNPs) and selection of four SNPs

	<i>FEN1</i> -10154G > T		<i>FADS2</i> rs174575		<i>FADS3</i> rs1000778		<i>FADS2</i> rs2727270		<i>FADS2</i> rs174576		<i>FADS2</i> rs174570		<i>FADS2</i> rs174583		<i>FADS3</i> rs174456	
	D'	r ²	D'	r ²	D'	r ²	D'	r ²	D'	r ²	D'	r ²	D'	r ²	D'	r ²
<i>FEN1</i> -10154G > T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>FADS2</i> rs174575	0.96	0.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>FADS3</i> rs1000778	0.21	0.04	0.46	0.04	-	-	-	-	-	-	-	-	-	-	-	-
<i>FADS2</i> rs2727270	0.98	0.71	1.00	0.03	0.13	0.01	-	-	-	-	-	-	-	-	-	-
<i>FADS2</i> rs174576	1.00	0.98	1.00	0.17	0.22	0.04	1.00	0.72	-	-	-	-	-	-	-	-
<i>FADS2</i> rs174570	1.00	0.98	1.00	0.17	0.21	0.04	0.99	0.71	1.00	0.99	-	-	-	-	-	-
<i>FADS2</i> rs174583	0.99	0.95	0.96	0.16	0.22	0.04	1.00	0.71	0.99	0.98	0.99	0.97	-	-	-	-
<i>FADS3</i> rs174456	0.21	0.04	0.46	0.04	1.00	1.00	0.01	0.01	0.22	0.04	0.21	0.04	0.22	0.04	-	-

Table S2 Associations of *FADS2* rs 2727270 genotypes with polyunsaturated fatty acid (PUFA) composition in serum phospholipids in men at baseline and 3-year follow-up

	<i>FADS2</i> rs 2727270 C>T						
	CC (n = 59)	P ^a	T allele (n = 63)	P ^a	P ^b	P ^c	
PUFA composition (%) in serum PL							
18:2 (ω6)							
Baseline	12.1 ± 0.38	0.971	12.0 ± 0.42	0.511	0.880		
Follow-up	12.1 ± 0.47		11.6 ± 0.45		0.455		
Change	0.02 ± 0.48		-0.38 ± 0.58		0.594		0.466
18:3 (ω6)							
Baseline	0.18 ± 0.02	0.215	0.16 ± 0.01	0.051	0.452		
Follow-up	0.20 ± 0.01		0.20 ± 0.01		0.693		
Change	0.02 ± 0.02		0.03 ± 0.02		0.666		0.756
20:2 (ω6)							
Baseline	0.59 ± 0.17	0.172	0.75 ± 0.18	0.024	0.508		
Follow-up	0.36 ± 0.03		0.51 ± 0.16		0.357		
Change	-0.23 ± 0.17		-0.24 ± 0.11		0.946		0.516
20:3 (ω6)							
Baseline	1.51 ± 0.06	0.974	1.36 ± 0.06	0.943	0.083		
Follow-up	1.52 ± 0.08		1.36 ± 0.07		0.123		
Change	0.00 ± 0.09		-0.01 ± 0.09		0.941		0.219
20:4 (ω6)							
Baseline	4.73 ± 0.20	0.027	3.99 ± 0.18	0.559	0.008		
Follow-up	5.42 ± 0.27		4.16 ± 0.23		0.001		
Change	0.69 ± 0.30		0.16 ± 0.28		0.206		0.003
18:3 (ω3)							
Baseline	0.17 ± 0.02	0.319	0.18 ± 0.03	0.945	0.912		
Follow-up	0.21 ± 0.02		0.18 ± 0.01		0.267		
Change	0.04 ± 0.03		0.00 ± 0.03		0.474		0.268
20:3 (ω3)							
Baseline	0.10 ± 0.02	0.029	0.08 ± 0.01	0.702	0.276		
Follow-up	0.06 ± 0.00		0.07 ± 0.00		0.123		
Change	-0.04 ± 0.02		-0.01 ± 0.01		0.138		0.128

(Continued)

Table 2 (Continued)

	FADS2 rs 2727270C>T					
	CC (n = 59)	P ^a	T allele (n = 63)	P ^a	P ^b	P ^c
20:5 (ω3)						
Baseline	1.18 ± 0.07	0.134	1.06 ± 0.07	0.585	0.240	
Follow-up	1.41 ± 0.12		1.11 ± 0.07		0.033	
Change	0.24 ± 0.16		0.05 ± 0.09		0.293	0.027
22:5 (ω3)						
Baseline	0.54 ± 0.03	0.088	0.60 ± 0.05	0.250	0.333	
Follow-up	0.63 ± 0.04		0.54 ± 0.04		0.085	
Change	0.09 ± 0.05		-0.06 ± 0.05		0.043	0.058
22:6 (ω3)						
Baseline	2.74 ± 0.18	0.130	2.69 ± 0.16	0.694	0.819	
Follow-up	3.10 ± 0.18		2.77 ± 0.18		0.205	
Change	0.36 ± 0.23		0.09 ± 0.22		0.399	0.215
20:4(ω6)/20:3(ω6)						
Baseline	3.24 ± 0.13	0.008	3.36 ± 0.39	0.798	0.785	
Follow-up	3.84 ± 0.22		3.25 ± 0.21		0.052	
Change	0.60 ± 0.22		-0.11 ± 0.41		0.134	0.043
20:4(ω6)/18:2(ω6)						
Baseline	0.42 ± 0.03	0.206	0.34 ± 0.02	0.232	0.024	
Follow-up	0.50 ± 0.06		0.42 ± 0.06		0.314	
Change	0.08 ± 0.06		0.07 ± 0.06		0.921	0.377
20:5(ω3)/18:3(ω3)						
Baseline	9.36 ± 0.79	0.148	9.18 ± 0.96	0.060	0.883	
Follow-up	7.88 ± 0.64		6.99 ± 0.58		0.306	
Change	-1.49 ± 1.01		-2.19 ± 1.14		0.646	0.307

Notes: ^aValues derived from paired *t*-test; ^bvalues derived from independent *t*-test; ^cvalues derived after adjusting for baseline values. Values are means ± standard error.

Abbreviations: PUFA, polyunsaturated fatty acid; PL, phospholipids

Table S3 Associations of *FADS2* rs2727270C genotypes with LDL cholesterol, hs-CRP, cytokines, and oxidative stress markers in men at baseline and 3-year follow-up

	<i>FADS2</i> rs2727270C > T					
	CC (n = 59)	P ^a	T allele (n = 63)	P ^a	P ^b	P ^c
LDL cholesterol (mg/dL)						
Baseline [§]	119.3 ± 4.14	0.035	114.9 ± 4.76	0.184	0.447	
Follow-up [§]	124.5 ± 3.46		119.2 ± 4.47		0.210	
Change	5.22 ± 2.98		4.26 ± 3.51		0.837	0.533
hs-CRP (mg/dL)						
Baseline [§]	1.34 ± 0.30	0.972	1.92 ± 0.77	0.534	0.606	
Follow-up [§]	1.45 ± 0.30		1.65 ± 0.49		0.947	
Change	0.11 ± 0.15		-0.27 ± 0.90		0.691	0.477
Serum IL-6 (pg/mL)						
Baseline [§]	4.27 ± 0.40	0.199	4.87 ± 0.52	0.006	0.407	
Follow-up [§]	3.87 ± 0.39		3.39 ± 0.34		0.474	
Change	-0.41 ± 0.46		-1.48 ± 0.61		0.168	0.268
Serum TNF- α (pg/mL)						
Baseline [§]	13.4 ± 1.73	0.765	9.53 ± 1.02	0.603	0.067	
Follow-up [§]	11.9 ± 1.68		8.87 ± 0.57		0.122	
Change	-1.42 ± 2.24		-0.66 ± 1.16		0.761	0.303
8-epi-PGF _{2α} (pg/mg creatinine)						
Baseline [§]	1313.0 ± 55.5	0.123	1324.3 ± 75.4	0.809	0.736	
Follow-up [§]	1484.1 ± 76.2		1243.3 ± 43.9		0.022	
Change	171.1 ± 93.2		-80.9 ± 85.1		0.048	0.003
Oxidized LDL (U/L)						
Baseline [§]	34.0 ± 1.61	<0.001	35.7 ± 1.96	<0.001	0.663	
Follow-up [§]	45.9 ± 1.49		43.4 ± 1.74		0.147	
Change	11.9 ± 1.65		7.76 ± 1.87		0.097	0.092

Notes: [§]Tested by logarithmic transformation; ^avalues derived from paired t-test; ^bvalues derived from independent t-test; ^cvalues derived after adjusting for baseline values. Values are means ± standard error.

Abbreviations: LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; TNF, tumor necrosis factor; IL, interleukin; 8-epi-PGF_{2 α} , urinary 8-epi-prostaglandin F_{2 α} .

Clinical Interventions in Aging

Dovepress

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, the American Chemical Society's 'Chemical Abstracts

Service' (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/clinical-interventions-in-aging-journal>